News
-
-
PRESS RELEASE
MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025
MIRA Pharmaceuticals announces progress in clinical development planning for novel oral ketamine analog, emphasizing early efficacy signal detection in humans by 2025. IND filing on schedule for December 2024 with focus on neuropathic pain treatment -
-
PRESS RELEASE
MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA
MIRA Pharmaceuticals, Inc. selects neuropathic pain as the primary indication for its novel oral ketamine analog, Ketamir-2, targeting neurologic disorders. Pre-IND meeting with FDA anticipated in Nov 2024 -
-
-
-
PRESS RELEASE
MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End
MIRA Pharmaceuticals, a leading pre-clinical-stage company, provides an update on its achievements and scientific advancements, nearing a milestone: IND application submission for Ketamir-2 and regulatory progress for MIRA-55 -
-
PRESS RELEASE
MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor
MIRA Pharmaceuticals unveils new preclinical data on innovative drug candidate Ketamir-2's metabolite Nor-Ketamir-2, showcasing enhanced bioavailability and formulation for advanced at-home neurological treatments